Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Effects of Donepezil Measured by Functional MRI

Start: May 2014
End: December 2021
Enrollment: 90

What Is This Study About?

Donepezil (brand name Aricept) is a medication commonly prescribed to treat Alzheimer's symptoms. This study will examine the sensitivity of functional magnetic resonance imaging (fMRI) to detect brain changes in healthy older adults at genetic risk for Alzheimer's disease who take donepezil. Participants with a family history of Alzheimer's will receive either 5 mg of donepezil for four weeks and 10 mg for 20 weeks or a placebo. Participants without a family history of Alzheimer's will undergo the study evaluations but will not receive the study drug. Researchers will measure the effects of donepezil on the brain using fMRI, a brain imaging method.

Do I Qualify To Participate in This Study?

Minimum Age: 60 Years

Maximum Age: 75 Years

Must have:

  • Normal cognitive function
  • Seeing and hearing ability adequate for neuropsychological testing
  • High-risk group only: family history of Alzheimer's (parent, sibling, or child with Alzheimer's)
  • Low-risk group only: no family history of Alzheimer's (no Alzheimer's in a parent, sibling, child, grandparent, grandchild, uncle, aunt, nephew, niece, or half-sibling)

Must NOT have:

  • Current or past history of neurological illnesses/conditions
  • Current or past history of head trauma with significant loss of consciousness
  • Current or past history of medical illnesses/conditions that may affect brain function
  • Severe psychiatric disorder
  • Substance abuse
  • Unstable or severe cardiovascular disease or asthmatic condition
  • History of stroke or transient ischemic attack

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: The Cleveland Clinic

Collaborator Sponsor

  • National Institute on Aging (NIA)

Source: ClinicalTrials.gov ID: NCT02087865

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health